Recap: Cardiff Oncology Q4 Earnings
Portfolio Pulse from Benzinga Insights
Cardiff Oncology (NASDAQ:CRDF) reported Q4 earnings with an EPS of $-0.21, beating estimates by 25.0% against an expected $-0.28. Revenue increased by $28 thousand from the same period last year. Despite beating EPS estimates in the past, such outcomes have previously led to a 3.0% drop in share price the following day.
February 29, 2024 | 9:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cardiff Oncology reported a Q4 EPS of $-0.21, surpassing estimates by 25%, with a revenue increase of $28K from the previous year. Historically, beating EPS estimates has led to a 3.0% share price drop the next day.
Despite Cardiff Oncology's positive earnings beat, historical data indicates that beating EPS estimates has previously resulted in a share price drop the following day. This pattern suggests a potential short-term negative impact on CRDF's stock price, although the company's improved financial performance could mitigate this effect.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100